By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Current study results on Biotechnology have been published. According to news reporting originating from Boston, Massachusetts, by NewsRx correspondents, research stated, "Multidrug resistance is the most widely exploited phenomenon by which cancer eludes chemotherapy. Broad variety of factors, ranging from the cellular ones, such as over-expression of efflux transporters, defective apoptotic machineries, and altered molecular targets, to the physiological factors such as higher interstitial fluid pressure, low extracellular pH, and formation of irregular tumor vasculature are responsible for multidrug resistance."
Our news editors obtained a quote from the research from Northeastern University, "A combination of various undesirable factors associated with biological surroundings together with poor solubility and instability of many potential therapeutic small & large molecules within the biological systems and systemic toxicity of chemotherapeutic agents has necessitated the need for nano-preparations to optimize drug delivery. The physiology of solid tumors presents numerous challenges for successful therapy. However, it also offers unique opportunities for the use of nanotechnology. Nanoparticles, up to 400 nm in size, have shown great promise for carrying, protecting and delivering potential therapeutic molecules with diverse physiological properties."
According to the news editors, the research concluded: "In this review, various factors responsible for the MDR and the use of nanotechnology to overcome the MDR, the use of spheroid culture as well as the current technique of producing microtumor tissues in vitro are discussed in detail."
For more information on this research see: Nanopreparations to overcome multidrug resistance in cancer. Advanced Drug Delivery Reviews, 2013;65(13-14):1748-1762. Advanced Drug Delivery Reviews can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; Advanced Drug Delivery Reviews - www.elsevier.com/wps/product/cws_home/505508)
The news editors report that additional information may be obtained by contacting N.R. Patel, Northeastern Univ, Center Pharmaceut Biotechnol & Nanomed, Boston, MA 02115, United States. Additional authors for this research include B.S. Pattni, A.H. Abouzeid and V.P. Torchilin (see also Biotechnology).
Keywords for this news article include: Biotechnology, Boston, Oncology, Chemotherapy, Massachusetts, United States, Nanotechnology, Drug Resistance, Cancer Gene Therapy, Emerging Technologies, North and Central America
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC